Effects of dipeptidyl peptidase-4 inhibitors on transforming growth factor-β1 signal transduction pathways in the ovarian fibrosis of polycystic ovary syndrome rats

Fang Wang¹,², Zhi-Fen Zhang¹, Yi-Ran He¹, Hong-Yan Wu¹ and Shuang-Shuang Wei¹

¹Department of Gynecology, The Affiliated Hangzhou Hospital of Nanjing Medical University, Hangzhou, Zhejiang and ²Department of Gynecology, Xuzhou Medical University Affiliated Hospital of Lianyungang, The First People’s Hospital of Lianyungang, Lianyungang, Jiangsu, China

Abstract

Aim: Examine the effects of dipeptidyl peptidase-4 (DPP4) inhibitor Sitagliptin on the transforming growth factor-β1 (TGF-β1) signal transduction pathway in polycystic ovary syndrome (PCOS) rats with ovarian fibrosis.

Methods: Thirty rats were divided randomly into the PCOS model group, Sitagliptin treatment group and blank control group. Dehydroepiandrosterone was administered to the model group and treatment group to establish the models. Then, the phenotype of rats was recorded, and the serum sex hormone levels were measured. The pathological structures of the rat ovaries were observed. The protein and mRNA expression levels of DPP4, connective tissue growth factor (CTGF), TGF-β1 and Smad2/3 in the ovaries were analyzed.

Results: There was no statistically difference in fasting body weight and blood glucose among the three groups before Sitagliptin treatment (P > 0.05). The fasting blood glucose level was significantly decreased after the administration of Sitagliptin (P < 0.05). The level of testosterone in the model group was reduced remarkably after Sitagliptin treatment (P < 0.001). The protein expression levels of DPP4, CTGF and TGF-β1 in the ovarian stroma were lower in the treatment group than in the model group (P < 0.01, P < 0.001, P < 0.05). The mRNA levels of DPP4, CTGF and TGF-β1 in the model group also greatly declined after Sitagliptin treatment (P < 0.01, P < 0.001, P < 0.01).

Conclusion: The DPP4 inhibitor Sitagliptin lowers fasting blood glucose, relieves the high androgen state of PCOS rats and delays the process of ovarian fibrosis, which may be related to reducing the levels of factors related to the TGF-β1/Smad2/3 signaling pathway.

Key words: endocrine, infertility, ovarian function, polycystic ovary syndrome.

Introduction

Polycystic ovary syndrome (PCOS) is characterized by clinical manifestations such as ovulation failure and insulin resistance. One of the mechanisms of ovulatory dysfunction is ovarian stromal fibrosis. The TGF-β1/Smad2/3 pathway is an important signaling pathway for tissue fibrosis, playing a significant role in the fibrotic diseases of various organ and tissue types. Researchers have confirmed that fibrosis is closely related to the synthesis of extracellular matrix (ECM) components. Many scholars have suggested this Signal pathways may be the key of tissue fibrosis.¹ Connective tissue growth factor (CTGF) is the downstream reaction element of transforming growth factor-β1 (TGF-β1) and can induce fibroblast proliferation and become involved in the formation of the ECM. Dipeptidyl peptidase-4 (DPP4) inhibitor has

Received: April 17 2018.
Accepted: October 2 2018.
Correspondence: Professor Zhi-Fen Zhang, Department of Gynecology, Obstetrics and Gynecology Hospital in Hangzhou, No. 369 Kunpeng Road, Hangzhou, 310008, China. Email: zhangzf@zju.edu.cn

© 2018 The Authors. Journal of Obstetrics and Gynaecology Research published by John Wiley & Sons Australia, Ltd on behalf of Japan Society of Obstetrics and Gynecology

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
been used to cure insulin resistance (IR) for a long time, and in recent years, DPP4 has been reported to work against fibrosis and inflammation. DPP4 can mitigate the fibrosis of viscus and organs, such as myocardium, liver, kidney and lung. However, there have not been any related reports on ovarian fibrosis. This research aimed to examine the effects of DPP4 inhibitor Sitagliptin on the PCOS rat model of ovarian fibrosis and evaluate the associated mechanism.

Methods

Animals

Thirty aseptic female Sprague–Dawley rats were used in this study. Rats were maintained according to the Guide for the Care and Use of Laboratory Animals. These 21-day-old rats, weighing 50–60 g, were purchased from the Animal Center of Zhejiang Academy of Medical Sciences. Other reagents were purchased as follows: Sitagliptin (Januvia) (Merck Sharp Dohme Ltd.), dehydroepiandrosterone (DHEA) (China Pharmaceutical Group Chemical Reagent Co. Ltd.) and injection-oriented camellia oil (Zhejiang Tianyushan Medicinal Oil Co. Ltd.).

Treatment

Thirty 21-day-old rats were fed standard forage and allowed to eat and drink freely. The rats were fed for 3 days, and the 24-day-old rats were randomly divided into the control group, model group and treatment group (10 rats per group). DHEA was dissolved in injection-oriented camellia oil; 0.2 mL of DHEA was injected at 6 mg/100 g daily subcutaneously in to the model group and treatment group, and the same amount of camellia oil was injected in to the control group. Vaginal smears were obtained from all rats beginning on the 11th day, and hypodermic injections and vaginal smears stopped being performed on the 20th day. Later, the treatment group was given 2 mL of Sitagliptin at 63 mg/100 g daily by gavage, while the control group and model group were given the same amount of distilled water for 28 days. Vaginal smears were obtained from all rats during the last 10 days.

After taking medications, all rats were weighed on an empty stomach; fasting blood glucose levels were measured in the morning; chloral hydrate (3.5 μL/g) was injected into the abdominal cavity to anesthetize the rats, and inferior blood was extracted from the postcava. Serum was collected after centrifugation and stored in a freezer (−80°C) for subsequent ELISA to measure the levels of testosterone (T), luteinizing hormone (LH), follicle-stimulating hormone (FSH), the LH/FSH ratio and anti-Mullerian hormone (AMH). The ovaries were weighed, and one was placed in 10% neutral formalin. The largest plane of the ovary was taken as the inspection plane for paraffin embedding, cut into slices continuously (4 μm thick) and pasted onto poly-l-lysine clean slices to prepare sections. Some were used for HE staining to observe the ovarian pathological structure, and some were used for immunohistochemical experiments after baking. The other ovary was frozen in liquid nitrogen for storage at −80°C (half for Western blot and half for PCR).

Immunohistochemistry

The expression levels of the DPP4, TGF-β1, Smad2/3 and CTGF in the ovarian stroma were tested. This study employed the streptomycin-biotin peroxidase immunohistochemical staining method (S-P Method). The primary antibodies were all goat anti-rabbit polyclonal antibodies, and the secondary antibodies were all goat anti-rat secondary antibodies. Counterstaining with hematoxylin and coloration with diaminobenzidine were performed. Analysis was carried out with the semiquantitative integral method. Ten fields of vision at high magnification were chosen randomly for every section to analyze the positive cell number and coloration strength. Scores were assigned according to the positive cell percentage as follows: 0 points for a positive cell percentage <6%, 1 point for a positive cell percentage from 6 to 25%, 2 points for a positive cell percentage from 26 to 50%, 3 points for a positive cell percentage from 51 to 75% and 4 points for a positive cell percentage >75%. Scores were assigned according to coloration strength as follows: 0 points for no staining, 1 point for light yellow staining, 2 points for yellow staining and 3 points for tan staining. The total score was calculated by multiplying the two groups of scores, and 0 points were classified as negative (−), 1–4 points were classified as weakly positive (+), 5–8 points were classified as positive (++) and 9–12 points were classified as strongly positive (++++).

Western blot analysis

The DPP4, TGF-β1, Smad2/3 and CTGF protein levels in the ovarian tissues were tested. The films were scanned, archived and decolorized by PhotoShop.
The optical density value of the target band was analyzed with an Alpha software analysis system, and the ratio of the target and gray level to the internal reference band gray level was calculated.

**Real-time quantitative polymerase chain reaction analysis**

The mRNA levels of DPP4, TGF-β1, Smad2/3 and CTGF in the ovarian tissues were analyzed. Total RNA was extracted with the Trizol method, and RNA concentrations and purity were tested with a Nanodrop 2000 spectrophotometer. RNA was reverse-transcribed into cDNA according to the instructions provided in the reverse transcriptase kit and amplified in accordance with the instructions provided in the PCR kit. The general reaction volume was 40 μL, and the PCR conditions were as follows: denaturation at 95°C for 10 min; 40 cycles of 60°C → 95°C for a melting curve and increases by increments of 1°C every 20 s. The ΔΔCT method was used to analyze the results. The primer manufacturer was Service Bio, and the specific primers were as follows: R-DPP4-S primer sequence AACCCCCACTCACCCTCAGAC and R-DPP4-A primer sequence GACCTGTTCGGGTTTC CTATCT, segment length 107 bp; R-Smad2-S primer sequence ACTGGCGCCTCCTGGATGACTAT and R- Smad2-A primer sequence AGAGAGTGGTAGGAG -GACAGTTGAGC, segment length 197 bp; R-Smad3-S primer sequence CGAGAACACTAACCTCCTCCGCT and R-Smad3-A primer sequence GTGGTTCATCTGGT TGGTCGCTA, segment length 112 bp; R-TGF-β1-S primer sequence CTGAGGAAGCCTGGGTGTG and R-TGF-β1-A primer sequence GGTGGTGTTGTTGT GTAGAGGG, segment length 140 bp; R-Ctgf-S primer sequence CCAACTATGATGCCGACCACT and R-Ctgf-A primer sequence TTAGGCCGGTAGGT CTTCACACT, segment length 272 bp.

**Statistical analyses**

Stata 14.0 was used for the analysis of the experimental data. The data were not in conformity with the test of normality and homoscedasticity. Thus, statistical analysis was carried out using a nonparametric test, quantitative materials were described as the interquartile range M (Q25, Q75), and the rank-sum test was used to make comparisons between groups. The Kruskal–Wallis test was conducted for ranked data to make comparisons between groups. P < 0.05 indicated a statistically significant difference.

**Results**

**Phenotypes**

There were no statistically significant differences in fasting body weight or blood glucose among the three groups before Sitagliptin treatment (P > 0.05, P > 0.05). After Sitagliptin treatment, the fasting blood glucose level in the treatment group was significantly lower than that in the model group (P < 0.05), but there were no significant differences in weight among the three groups (P > 0.05). Changes in the estrus cycles of the three groups of rats were also evaluated. After the establishment of the PCOS model and before Sitagliptin treatment, the rats in the blank control group had regular estrus cycles. The other two groups had no normal estrus cycles. Though there was still no regular estrus cycle in the treatment group, pre-estrus were the main stages observed, while dioestrus mainly for model group.

**Evaluation of models**

After vaginal smears were collected for 10 days continuously, regular estrus cycles were observed in all rats of the control group, while 90% of the PCOS group did not have normal estrus cycles; thus, the PCOS models were built successfully for the preliminary assessment. A morphological comparison was made by HE staining of rat ovarian tissues after all treatments (Fig. 1). In the control group, the ovaries were in good condition, and the follicles and corpora lutea of the different development all stages were visible (Fig. 1a). In the PCOS model group, the ovarian volume was unusually increased, and there were a large number of unusually enlarged follicles within the ovaries. The theca cells and cellular layers of the follicles were thickened, the granular cell layers had become thinner and granular cell placement was chaotic. Some of the follicles underwent vacuolar degeneration and necrosis. A large amount of ovarian follicular fluid filled the follicles, and leukocytes were visible in a small amount of ovarian follicular fluid (Fig. 1b). The PCOS rat models were built successfully for further evaluation. Additionally, the Sitagliptin treatment group showed a regular ovarian structure, fewer unusually increased follicles, no obvious increase in theca cell layers of follicular cells and an organized arrangement of granular cells (Fig. 1c).

**Comparison of serum hormone levels**

The concentrations of T and AMH in the serum increased in the PCOS model group (P < 0.001, P < 0.01) compared with the control group, but the
LH/FSH ratio was not statistically significant ($P > 0.05$). The levels of T in the Sitagliptin treatment group were reduced compared with those in the PCOS model group ($P < 0.01$), but the differences in AMH and LH/FSH were not statistically significant between the treatment and model groups ($P > 0.05$) (Fig. 2).

**Protein expression levels of DPP4, TGF-β1, Smad2/3 and CTGF in the ovary**

Comparison of the protein levels of DPP4, TGF-β1, Smad2/3 and CTGF in the whole ovary

The protein levels of DPP4 in the PCOS model group rose noticeably ($P < 0.001$) compared with those in the control group, and the levels of TGF-β1 and CTGF increased ($P < 0.01$). The protein levels of TGF-β1 were reduced in the Sitagliptin treatment group ($P < 0.001$), and those of DPP4 and CTGF were decreased ($P < 0.01$). There was no statistical significance regarding Smad2 or Smad3 among the three groups ($P > 0.05$) (Fig. 3).

Comparison of the protein levels of DPP4, TGF-β1, Smad2/3 and CTGF in the ovarian stroma

The DPP4, TGF-β1, Smad2/3 and CTGF proteins were expressed in the ovarian stroma of rats. A comparison of the PCOS model group with the treatment group showed that the expression levels of DPP4, CTGF, TGF-β1, Smad2 and Smad3 were all increased in the ovarian stroma of the rats, with notable differences for TGF-β1, Smad2 and Smad3 ($P < 0.001$). A comparison of the Sitagliptin treatment group with the PCOS model group showed that the protein expression intensity of DPP4, TGF-β1 and Smad3 was notably decreased ($P < 0.001$), but this decrease was not observed for Smad2 or CTGF (Table 1) (Fig. 4).
mRNA expression levels of DPP4, CTGF, TGF-β1 and Smad2/3 in the ovaries

In comparisons involving the 2−ΔΔCt value, the mRNA level of DPP4 in the PCOS model increased notably compared with that in the control group (P < 0.001) and increased for TGF-β1 and CTGF (P < 0.05), while the mRNA levels of DPP4, TGF-β1 and CTGF in the Sitagliptin treatment group decreased compared with those in the PCOS model group (P < 0.05). The differences in the mRNA levels of Smad2 and Smad3 were not statistically significant among the three groups (P > 0.05) (Fig. 5).

Discussion

PCOS patients have a difficulty in pregnancy. The primary cause of this difficulty is ovulatory dysfunction,
Figure 4 Proteins’ expressions of dipeptidyl peptidase-4 (DPP4), connective tissue growth factor (CTGF) and transforming growth factor-β1 (TGF-β1) in ovarian stroma for each group (×400): the expressions of DPP4, CTGF and TGF-β1 in ovarian stroma of the polycystic ovary syndrome (PCOS) group were strongly positive, while they were noticeably weaker in both the treatment group and the control group.

Figure 5 RT-PCR was conducted to test and analyze dipeptidyl peptidase-4 (DPP4), transforming growth factor-β1 (TGF-β1) and connective tissue growth factor (CTGF) mRNAs’ 2-ΔΔCt: the data was analyzed and described by interquartile range M (Q25, Q75). (a) DPP4: the data of the model group 5.55 (4.80, 5.78) increased notably compared with that of the control group 3.28 (3.02, 3.91) (P < 0.01), while that of the treatment group 3.54 (3.26, 4.12) decreased compared with that of the model group (P < 0.05); (b) TGF-β1: the data of the model group 0.98 (0.80, 0.98) increased notably compared with that of the control group 0.45 (0.39, 0.65) (P < 0.01), while that of the treatment group 0.49 (0.32, 0.85) greatly decreased compared with that of the model group (P < 0.001); (c) CTGF: the data of the model group 5.10 (4.14, 5.57) notably increased compared with that of the control group 3.47 (2.71, 4.26) (P < 0.01), while that of the treatment group 3.69 (3.08, 4.14) decreased (P < 0.05) compared with that of the model group; (c) Smad2; (d) Smad3: there was no statistical significance among the three groups. Control ■, model □, treatment ▲.
and one of the mechanisms of ovulatory failure is ovarian fibrosis, which mainly occurs in the stroma. Currently, there are no effective treatment measures for reducing ovarian fibrosis in PCOS patients. DPP4 is also called adenosine deaminase binding protein or CD26. DPP4 was first discovered in 1963 and belongs to the S9 protease family. As a multifunctional protein, DPP4 is involved in different biological processes, including inflammation, aggressive transformation and tumor immunity. DPP4 inhibitors have long been applied to treat islet resistance. In recent years, there have been reports on its antifibrosis effects. DPP4 is also expressed in many types of cells, such as epithelial cells, endothelial cells, marrow cells, adipose cells, skeletal muscle cells and vascular smooth muscle cells. Sitagliptin, one of the most common medicines of DPP4 inhibitors, is mainly used for therapy in patients with diabetes who are metformin insensitive. Okura et al. suggested that DPP4 had anti-inflammatory and antioxidant effects and could mitigate the hepatic fibrosis levels of patients with cirrhosis. Researchers have shown that the antifibrosis effects of Sitagliptin may inhibit the TGF-β1/Smad2/3 signal transduction pathway to activate hematopoietic stem cells and inhibit collagen synthesis, thus influencing the fibrosis process. TGF-β1 is closely related to tissue fibrosis, promoting tissue fibrosis by increasing the levels of ECM components. The TGF-β1/Smad2/3 pathway is an important signaling pathway for tissue fibrosis. Research by Inagaki and Okazaki showed that hepatic fibrosis was closely related to the TGF-β1/Smad signaling pathway. However, there have not been any studies on whether this pathway is related to ovarian fibrosis in PCOS. Researchers have also shown that the TGF-β1 level in the serum of PCOS patients is relatively higher than that in the serum of normal patients. The ovarian fibrosis of PCOS patients is suggested to be potentially related to increases in TGF-β1 levels.

In our study, the serum levels of T and AMH in the PCOS rats were relatively high, which was possibly related to DHEA-induced PCOS. Although Sitagliptin could not reduce the LH/FSH ratio, Sitagliptin lowered the T level to some degree. The decrease in T very likely played a role in the improved endocrine function of the PCOS rats, which was consistent with previous reports. The reductions in the levels of T and AMH in the PCOS rats by the DPP4 inhibitor are presumably related to several mechanisms. (i) Miao found that the follicle-mesenchymal cells in the ovaries of PCOS patients were rich in smooth endoplasmic reticulum, lipid droplets and mitochondria, forming typical steroid hormone cells, which indicated that the ability to synthesize androgens in theca-interstitial cells was higher for PCOS patients than normal. Additionally, the expression of TGF-β1 in theca-interstitial cells in PCOS patients was significantly higher than normal. This finding suggested that the high expression of TGF-β1 might be related to the occurrence of hyperandrogenism. DPP4 inhibitors reduce excessive DPP4 and might mitigate ovarian tissue fibrosis and reduce androgen levels indirectly. (ii) IR was present in the majority of PCOS patients, and high insulin could directly stimulate follicles, causing secretory excessive androgen, promoting follicle enlargement and increasing the amount of sinus follicular. AMH is mainly secreted by the granular cells of the small sinus follicle, and IR leads to an increase in AMH indirectly. The DPP4 inhibitor was found to be useful for regulating the proliferation and apoptosis of beta cells in islets, inhibiting the secretion of glucagon and the formation of endogenous glucose and the DPP4 inhibitor has the positive effect of reducing blood sugar and improving islet function. Therefore, alleviating IR in PCOS patients can indirectly reduce T and AMH levels.

In this study, the effect of the DPP4 inhibitor Sitagliptin on the weight of PCOS rats was not obvious, which may be related to the short time of administration or the small number of cases. However, we found that this drug had some effect on the estrus cycle of PCOS rats and could push estrus from diestrus into pre-estrus. Is it possible to induce normal estrus cycles in PCOS rats after long-term administration? The reason may be related to the reduction in T and AMH by the DPP4 inhibitor. This problem needs further consideration and additional studies.

The results of this research showed that the ovarian morphology of the treatment group had been improved, with a relatively smaller number of accumulating granular cells and a regular arrangement, which might be related to the anti-inflammatory effect of Sitagliptin. In addition, we found that DPP4 could be expressed in the fibroblasts, fiber cells, theca cells and granular cells of rat ovaries, mainly in the stroma. For PCOS rats, the expression of DPP4 in the ovarian stroma was obviously stronger than that of the control group, and the over expression of DPP4 was estimated to have a certain correlation with the occurrence of PCOS. Additionally, in the rat ovarian tissue, we found that molecules associated with the TGF-β1/Smad2/3 signal transduction pathway, which
is closely related to tissue fibrosis, showed notably stronger expression, and we observed stronger expression of the CTGF protein, which lies downstream. These molecules were intensely expressed in the fibroblasts and fiber cells of the ovarian stroma while weakly positive or negative in theca cells and granular cells. In a further analysis of mRNA and total protein levels, we found that the mRNA and total protein expression levels of DPP4, TGF-β1 and CTGF in the ovaries of PCOS rats were obviously higher than those in the ovaries of the control group, which showed that there were synergistic actions among DPP4, TGF-β1 and CTGF during the occurrence of PCOS.

In this study, we had also found that the expression intensities of DPP4, TGF-β1, Smad2, Smad3 and CTGF in the rat ovarian stroma were weakened in the PCOS treatment group after rats were treated with the DPP4 inhibitor Sitagliptin. The mRNA and total protein levels of DPP4, TGF-β1 and CTGF were noticeably decreased, but no difference was observed in the levels of Smad2 or Smad3, which was probably related to the regional distribution of Smad2 and Smad3, the small specimen quantity of this research, or the improper dosage of Siglitatin. This conclusion indicated that the DPP4 inhibitor Siglitatin could mitigate ovarian fibrosis in PCOS rats. This action might come into effect through the TGF-β1/Smad2/3 signal transduction pathway and its downstream functional element CTGF. Kosuke Kaji proposed that low-dose Siglitatin could inhibit the synthesis of collagen fibers through the ERK1/2, p38 and TGF-β1/Smad2/3 pathways during hepatic fibrosis inhibition. Siglitatin was also reported to alter different genes that are involved in inflammation, fibrosis and cell growth through the JAK/STAT signal transduction pathway. Thus, there are likely other pathways for DPP4 inhibitor-mediated anti-ovarian fibrosis.

Previous studies have shown that DPP4 can stimulate an increase in stromal cell-derived factor 1 (SDF-1, also called CXCL12). SDF-1 increases cAMP levels, ROS and TGF-β1 levels within a tissue, thus activating the TGF-β1/Smad2/3 signaling pathway and its downstream elements, causing tissue fibrosis. On this basis, we infer that the antifibrosis mechanism of the DPP4 inhibitor Siglitatin may be that after inhibiting DPP4 expression, Siglitatin reduces SDF-1 levels and blocks the TGF-β1/Smad2/3 signaling pathway and its downstream element CTGF, thus alleviating tissue fibrosis. DPP4 is somewhat related to the occurrence and development of PCOS. PCOS patients usually suffer abnormal metabolism. DPP4 inhibitors can help patients with diabetes decrease IR, reduce glycated hemoglobin and reduce abnormally increased alanine aminotransferase and aspartate aminotransferase in the liver. The inhibition of DPP4 expression is expected to reduce ovarian fibrosis and reduce islet resistance. For patients with PCOS combined with islet resistance, DPP4 inhibition can hopefully be a new option for treatment.

Acknowledgments

The authors are grateful to all members of the Department of Gynecology for their helpful discussion, The Affiliated Hangzhou Hospital of Nanjing Medical University and support from The Major Science and Technology Program in Hangzhou (NO: 2014C03044-1). The authors have no potential conflicts of interest.

Disclosure

No conflict of interest is declared.

References

1. Verrecchia F, Mauviel A. Transforming growth factor-beta and fibrosis. World J Gastroenterol 2007; 13: 3056–3062.
2. Muliwihl Erin E, Varin Elodie M, Ussher John R et al. Inhibition of dipeptidyl peptidase-4 impairs ventricular function and promotes cardiac fibrosis in high fat-fed diabetic mice. Diabetes 2016; 65: 742–754.
3. Klein T, Fujii M, Sabel J et al. Linagliptin alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis. Med Mol Morphol 2014; 47: 137–149.
4. Eckhardt M, Langkopf E, Mark M et al. (R)-(aminopiperidin-1-y1)-7-but-2-ynyl-3-methyl - 1 - (4 -methyl-quinazolin-2-ylmethyl)-3, 7-dihydropurine-2,6-dione (bi 1356), a highly potent, selective, long-acting, and orally bioavailable dpp-4 inhibitor for the treatment of type 2 diabetes. J Med Chem 2008; 50: 6450–6453.
5. Gorrell MD, Park JE. Chapter 750 – Fibroblast activation protein α. In: Handbook of Proteolytic Enzymes. Rawlings, Neil D; Academic Press, 2013; 3395–3401.
6. Kajiyama H, Kikawaka F, Maeda O, Suzuki T, Ino K, Mizutani S. Increased expression of dipeptidyl peptidase iv in human mesothelial cells by malignant ascites from ovarian carcinoma patients. Oncology 2002; 63: 158–165.
7. Barreira DSR, Laird ME, Yatim N, Fiette L, Ingersoll MA, Albert ML. Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy. Nat Immunol 2015; 16: 850–858.
8. Matheeussen V, Baerts L, De MG et al. Expression and spatial heterogeneity of dipeptidyl peptidases in endothelial cells of conduct vessels and capillaries. Biochim Biophys Acta 2011; 1812: 189–198.

9. Klemann C, Wagner L, Stephan M, Von HS. Cut to the chase: A review of cd26/dipeptidyl peptidase-4 (dpp4)’s entanglement in the immune system. Clin Exp Immunol 2016; 185: 1–21.

10. Wang Z, Grigo C, Steinbeck J, Von HS, Amann K, Daniel C. Soluble dpp4 originates in part from bone marrow cells and not from the kidney. Peptides 2014; 57: 109–117.

11. Lamers D, Famulla S, Wronkowitz N et al. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes 2011; 60: 1917–1925.

12. Raschke S, Eckardt K, Bjorklund HK, Jensen J, Eckel J. Identification and validation of novel contraction-regulated myokines released from primary human skeletal muscle cells. PLoS One 2013; 8: 1371–1376.

13. Röhrborn D, Eckel J, Sell H. Shedding of dipeptidyl peptidase 4 is mediated by metalloproteases and up-regulated by hypoxia in human adipocytes and smooth muscle cells. FEBS Lett 2014; 588: 3870–3877.

14. Okura Y, Namisaki T, Moriya K et al. Combination treatment of dipeptidyl peptidase iv inhibitor (sitagliptin) and angiotensinii type 1 receptor blocker (losartan) suppresses progression in a nondiabetic rat model of steatohepatitis. Hepatol Res 2017; 47: 1317–1328. https://doi.org/10.1111/hepr.12860.

15. Kaji K, Yoshiji H, Ikenaka Y et al. Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats. J Gastroenterol Hepatol 2014; 49: 481–491.

16. Lang Q, Liu Q, Xu N et al. The antifibrotic effects of tgf-β1 sima on hepatic fibrosis in rats. Biochem Biophys Res Commun 2011; 409: 448–453.

17. Satish L, Gallo PH, Baratz ME, Johnson S, Kathju S. Reversal of tgf-β1 stimulation of α-smooth muscle actin and extracellular matrix components by cyclic amp in Dupuytren’s – derived fibroblasts. BMC Musculoskelet Disord 2011; 12: 113–120.

18. Yang L, Chan CC, Kwon OS et al. Regulation of peroxisome proliferator-activated receptor-gamma in liver fibrosis. Am J Physiol Gastrointest Liver Physiol 2010; 299: 902–911.

19. Inagaki Y, Okazaki I. Emerging insights into transforming growth factor beta smad signal in hepatic fibrogenesis. Gut 2007; 56: 284–292.

20. Schiller M, Javelaud D, Mauviel A. Tgf-β1-induced smad signaling and gene regulation: Consequences for extracellular matrix remodeling and wound healing. J Dermatol Sci 2004; 35: 83–92.

21. Schaafsma D, Mcneill KD, Mutawe MM et al. Simvastatin inhibits tgfβ1-induced fibronectin in human airway fibroblasts. Respir Res 2011; 12: 1–10.

22. Miao ZL, Wang ZN, Yang YD, Chen LQ, Wang XL, Ou RQ. Role of TGF -β1 in the formation of ovarian interstitial fibrosis in PCOS rat. J Reprod Contracept 2008; 19: 83–92.

23. Jason L, Marcel J, Henry A, Spiller HA, Maria MZ. Clinical effects of exposure to DPP-4inhibitors as reported to the national oisondata system. J Med Toxicol 2014; 10: 152–155.

24. Lee TI, Kao YH, Chen YC, Huang JH, Hsu MI, Chen YJ. The dipeptidyl peptidase-4 inhibitor-sitagliptin modulates calcium dysregulation, inflammation, and pparαs in hypertensive cardiomyocytes. Int J Cardiol 2013; 168: 5390–5395.

25. Al-Rasheed NM, Al-Rasheed NM, Hasan IH, Al-Amin MA, Al-Ajmi HN, Mahmoud AM. Sitagliptin attenuates cardiomyopathy by modulating the jak/stat signaling pathway in experimental diabetic rats. Drug Des Dev Ther 2017; 10: 2095–2017.

26. Kiu H, Nicholson SE. Biology and significance of the jak/-stat signalling pathways. Growth Factors 2016; 30: 88–106.

27. Zhong J, Rajagopalan S. Dipeptidyl peptidase-4 regulation of sdf-1/cxcr4 axis: Implications for cardiovascular disease. Front Immunol 2015; 6: 477.

28. Kanazawa I, Tanaka KI, Sugimoto T. Dpp-4 inhibitors improve liver dysfunction in type 2 diabetes mellitus. Med Sci Monit 2014; 20: 1662–1667.